BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2019

View Archived Issues

How starved cancers grow

Read More

Twin study identifies novel genetic mutations causing hypospadias

Read More

MolMed receives authorization to initiates phase I/II study of CAR T CD44v6 cells

Read More

Hypoxia has unexpected range of effects in antitumor therapy

Read More

Development of a novel PDX model of human prostate cancer

Read More

e-Therapeutics patents new hedgehog signaling inhibitors

Read More

Chronos Therapeutics presents orexin receptor antagonists

Read More

Selective delipidation of BCG vaccine enhances protection and enables direct pulmonary vaccination

Read More

Netherlands Translational Research Center divulges IDO1 inhibitors

Read More

XW Laboratories identifies ROS production inhibitors

Read More

Janssen Pharmaceutica describes HCV NS5B inhibitors

Read More

First patients receive treatment in phase IIa study of ModraDoc006/r in metastatic breast cancer

Read More

Trizell initiates phase III study of gene therapy TR-002 for malignant pleural mesothelioma

Read More

Eisai initiates phase III study of BAN-2401 in early Alzheimer's disease

Read More

BEECH study finds no survival benefit of adding capivasertib to paclitaxel for breast cancer

Read More

Pleckstrin-2 as a novel diagnostic biomarker in JAK2V617F-positive myeloproliferative neoplasms

Read More

Conatus reports ENCORE-NF topline results for emricasan in NASH and liver fibrosis

Read More

New PLAG1 gene variations tied to lipoblastoma

Read More

Evox secures funding to support development of exosome therapy to treat argininosuccinic aciduria

Read More

Exscientia and Celgene enter AI-led drug discovery partnership in oncology and autoimmunity

Read More

LegoChem and Takeda form ADC research collaboration and license agreement in immuno-oncology

Read More

Sihuan demonstrates proof of mechanism with CDK4/6 inhibitor birociclib in phase I

Read More

Unusual anti-inflammatory meroterpenoids isolated from the marine sponge Dysidea septosa

Read More

AZGP1 is correlated with HPV positivity in oropharyngeal squamous cell carcinoma

Read More

GATA-3 is a new biomarker of gonadotroph adenomas

Read More

Nuformix begins clinical trial of NXP-001 for CINV

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 17, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • EU flag vector

    European Commission floats multiple fixes for MDR, IVDR

    BioWorld MedTech
    The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing